Xenon Pharmaceuticals Inc. XENE-Q generated positive results from a critical late-stage human trial for its epilepsy ...

Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026. ・CEO Ian Mortimer said ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

An international clinical trial has achieved a new effective treatment option for rare epilepsy that can reduce seizures by 91% in children. Here is what this breakthrough means for the children ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain to "remember" how to trigger subsequent seizures more easily, a small ...

Families say the groundbreaking medicine is transforming the lives of children with Dravet syndrome.

A pioneering gene therapy could help treat a rare seizure disorder called Dravet syndrome, according to new clinical trial ...

Following the results of an extensive survey by researchers at Arizona State University and the University of Texas-Houston, medical professionals and parents now have a better guide for treating ...

Patients who have seizures may receive faster and more effective treatment because of a collaboration between the UA and the National Institutes of Health. Seventeen emergency medical centers and 33 ...